Search - tctmd.com

Displaying 361 - 380 of 831

Sort: Relevancy | Date

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

News Conference News TCT 2016

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Michael O'Riordan

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Editorial Perspective: CTO Therapies: Market Size and Technical Needs in 2016

Presenter: Craig A. Thompson

October 31, 2016

News Conference News TCT 2016

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

Todd Neale

October 30, 2016

News Conference News TCT 2016

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

TCT Daily Staff

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Presentation TCT 2016

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Gregg W. Stone

October 30, 2016

Presentation TCT 2016

Points to Consider in the Review of Endovascular Treatment Devices: US Regulatory View

Presenter: Schuyler Jones, Misti Malone, Eleni Whatley

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Harvey D. White

October 30, 2016

Presentation TCT 2016

Points To Consider in the Review of Endovascular Treatment Devices: Japanese Regulatory View

Presenter: Schuyler Jones, Misti Malone, Shin Iwamoto

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann, Jorge F. Saucedo

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Atherectomy

Presenter: Schuyler Jones, Misti Malone, Brad Martinsen, PhD

October 30, 2016

Presentation TCT 2016

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Presenter: A. Michael Lincoff, Franz-Josef Neumann

October 30, 2016

Presentation TCT 2016

Overview of the Clinical Trials for Drug-Coated Balloons

Presenter: Schuyler Jones, Misti Malone, George Papandreou

October 30, 2016

Presentation TCT 2016

Japan Academia View

Presenter: Schuyler Jones, Misti Malone, Hiroyoshi Yokoi

October 30, 2016

Presentation TCT 2016

US Academia View

Presenter: Schuyler Jones, Misti Malone, Michael R. Jaff

October 30, 2016

Advertisement

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Interventionalists Push Transradial PCI in Wider Range of Settings, Including ACS, CTOs, and Calcified Lesions

EXCEL 和 NOBLE：左主干 PCI/CABG 的选择结果相悖

EXCEL y NOBLE: Los Resultados Contrarios Plantean un Dilema a la Hora de Elegir entre PCI y CABG en el Manejo de la Enfermedad de Tronco Coronario Izdo.

EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Editorial Perspective: CTO Therapies: Market Size and Technical Needs in 2016

Are Full, Formal Guidelines Still Useful in the Rapidly Changing TAVR Field?

BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Should Bivalirudin Only Be Used With a Prolonged Post-PCI Infusion?

Points to Consider in the Review of Endovascular Treatment Devices: US Regulatory View

Start With a Three-way Debate: Bivalirudin Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Points To Consider in the Review of Endovascular Treatment Devices: Japanese Regulatory View

Start With a Three-way Debate: Heparin Plus Routine Use of GP IIb/IIIa Inhibitors Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Overview of the Clinical Trials for Atherectomy

Start With a Three-way Debate: Heparin Monotherapy Is the Optimal Procedural Anticoagulant in STEMI Patients Undergoing Primary PCI!

Overview of the Clinical Trials for Drug-Coated Balloons

Japan Academia View

US Academia View

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content